Nifty
Sensex
:
:
11521.05
38386.75
-11.35 (-0.10%)
23.28 (0.06%)

Pharmaceuticals & Drugs

Rating :
48/99

BSE: 524404 | NSE: MARKSANS

24.75
-0.30 (-1.20%)
20-Mar-2019 | 3:56PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  25.35
  •  25.45
  •  24.70
  •  25.05
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  860498
  •  212.97
  •  40.60
  •  21.95

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,023.28
  • 16.78
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,101.37
  • 0.20%
  • 1.88

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 48.25%
  • 4.14%
  • 41.03%
  • FII
  • DII
  • Others
  • 0.32%
  • 0.97%
  • 5.29%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.87
  • 7.70
  • 0.72

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.73
  • -7.21
  • -9.96

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 38.17
  • -14.45
  • -25.14

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.00
  • 32.37
  • 40.40

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.05
  • 5.76
  • 3.51

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 11.97
  • 18.37
  • 20.96

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Net Sales
248.37
218.43
13.71%
269.04
273.81
-1.74%
235.25
221.06
6.42%
199.32
178.03
11.96%
Expenses
212.18
189.58
11.92%
231.92
249.22
-6.94%
199.77
192.06
4.01%
195.33
177.19
10.24%
EBITDA
36.19
28.85
25.44%
37.12
24.59
50.96%
35.49
29.00
22.38%
3.99
0.84
375.00%
EBIDTM
14.57%
13.21%
13.80%
8.98%
15.08%
13.12%
2.00%
0.47%
Other Income
0.16
0.39
-58.97%
-0.80
0.00
-
3.23
0.04
7,975.00%
0.00
6.90
-100.00%
Interest
1.76
1.76
0.00%
3.06
3.04
0.66%
2.40
1.94
23.71%
3.47
1.57
121.02%
Depreciation
5.04
6.23
-19.10%
5.54
6.97
-20.52%
5.96
7.45
-20.00%
6.19
7.54
-17.90%
PBT
29.55
21.25
39.06%
27.72
14.57
90.25%
30.36
19.66
54.43%
-5.68
-1.36
-
Tax
4.42
3.79
16.62%
7.15
4.16
71.88%
5.48
5.24
4.58%
0.80
1.84
-56.52%
PAT
25.13
17.46
43.93%
20.57
10.41
97.60%
24.88
14.42
72.54%
-6.48
-3.20
-
PATM
10.12%
7.99%
7.65%
3.80%
10.57%
6.52%
-3.25%
-1.80%
EPS
0.60
0.41
46.34%
0.48
0.23
108.70%
0.58
0.33
75.76%
-0.17
-0.08
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
951.98
912.69
767.16
893.33
796.69
630.00
438.42
355.55
304.58
357.55
356.10
Net Sales Growth
6.80%
18.97%
-14.12%
12.13%
26.46%
43.70%
23.31%
16.73%
-14.81%
0.41%
 
Cost Of Goods Sold
481.42
523.13
458.74
509.69
445.44
367.93
252.86
212.92
202.80
256.69
242.91
Gross Profit
470.56
389.57
308.42
383.63
351.25
262.07
185.56
142.62
101.78
100.86
113.18
GP Margin
49.43%
42.68%
40.20%
42.94%
44.09%
41.60%
42.32%
40.11%
33.42%
28.21%
31.78%
Total Expenditure
839.20
834.31
734.24
760.91
620.86
516.04
369.02
455.33
460.00
333.91
334.45
Power & Fuel Cost
-
11.83
13.27
12.58
9.72
7.80
6.12
4.89
4.99
6.05
7.14
% Of Sales
-
1.30%
1.73%
1.41%
1.22%
1.24%
1.40%
1.38%
1.64%
1.69%
2.01%
Employee Cost
-
147.75
149.70
122.42
72.61
66.44
55.91
45.70
36.26
35.38
36.80
% Of Sales
-
16.19%
19.51%
13.70%
9.11%
10.55%
12.75%
12.85%
11.90%
9.90%
10.33%
Manufacturing Exp.
-
62.72
47.34
50.44
37.59
30.11
9.85
8.76
8.75
8.98
9.78
% Of Sales
-
6.87%
6.17%
5.65%
4.72%
4.78%
2.25%
2.46%
2.87%
2.51%
2.75%
General & Admin Exp.
-
39.69
37.52
36.01
15.35
16.13
24.93
21.00
15.56
16.71
14.81
% Of Sales
-
4.35%
4.89%
4.03%
1.93%
2.56%
5.69%
5.91%
5.11%
4.67%
4.16%
Selling & Distn. Exp.
-
49.14
27.66
29.77
34.47
27.63
22.84
17.39
21.08
9.28
15.41
% Of Sales
-
5.38%
3.61%
3.33%
4.33%
4.39%
5.21%
4.89%
6.92%
2.60%
4.33%
Miscellaneous Exp.
-
0.05
0.00
0.00
5.67
0.00
-3.49
144.66
170.58
0.81
15.41
% Of Sales
-
0.01%
0%
0%
0.71%
0%
-0.80%
40.69%
56.00%
0.23%
2.13%
EBITDA
112.79
78.38
32.92
132.42
175.83
113.96
69.40
-99.78
-155.42
23.64
21.65
EBITDA Margin
11.85%
8.59%
4.29%
14.82%
22.07%
18.09%
15.83%
-28.06%
-51.03%
6.61%
6.08%
Other Income
2.59
8.47
18.85
12.72
12.23
7.28
4.40
2.05
3.62
1.84
8.06
Interest
10.69
10.22
6.78
10.16
16.05
19.13
14.60
53.58
43.67
19.23
21.36
Depreciation
22.73
26.84
30.09
28.13
16.13
15.69
15.65
23.70
19.98
15.47
15.35
PBT
81.95
49.80
14.90
106.85
155.88
86.41
43.55
-175.00
-215.44
-9.23
-7.00
Tax
17.85
14.00
3.56
24.11
43.92
12.79
-5.28
1.08
6.41
0.40
0.96
Tax Rate
21.78%
28.11%
23.89%
22.56%
28.18%
14.80%
-12.12%
-0.62%
-2.98%
-4.33%
-13.71%
PAT
64.10
32.94
8.83
78.51
109.39
71.90
45.89
-178.84
-223.25
-10.04
-8.35
PAT before Minority Interest
60.99
35.80
11.33
82.74
111.96
73.62
48.83
-176.08
-221.86
-9.62
-7.95
Minority Interest
-3.11
-2.86
-2.50
-4.23
-2.57
-1.72
-2.94
-2.76
-1.39
-0.42
-0.40
PAT Margin
6.73%
3.61%
1.15%
8.79%
13.73%
11.41%
10.47%
-50.30%
-73.30%
-2.81%
-2.34%
PAT Growth
63.98%
273.05%
-88.75%
-28.23%
52.14%
56.68%
-
-
-
-
 
Unadjusted EPS
1.49
0.80
0.22
1.92
2.67
1.87
1.19
-4.86
-6.07
0.00
0.00

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
470.86
433.43
454.32
379.76
142.18
86.48
-168.07
-62.61
161.09
150.29
Share Capital
40.93
40.93
53.43
53.43
52.03
52.03
50.28
50.28
50.28
50.28
Total Reserves
429.93
392.50
400.89
326.33
90.15
34.45
-219.51
-115.40
110.81
100.01
Non-Current Liabilities
15.64
16.07
-1.91
1.46
22.16
10.49
28.26
34.72
436.24
408.50
Secured Loans
0.00
0.00
0.00
0.00
19.82
7.88
15.20
19.00
247.07
195.21
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
176.96
201.32
Long Term Provisions
1.08
0.96
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Liabilities
233.09
296.06
259.43
286.24
319.12
297.28
519.26
519.79
59.55
82.12
Trade Payables
67.48
161.78
118.98
107.02
83.18
56.06
58.62
55.11
59.46
81.08
Other Current Liabilities
1.26
0.71
0.68
39.88
96.58
108.73
336.39
341.76
0.00
0.01
Short Term Borrowings
117.41
109.71
87.89
82.19
105.54
113.79
113.92
115.98
0.00
0.00
Short Term Provisions
46.94
23.85
51.88
57.15
33.82
18.70
10.32
6.93
0.09
1.03
Total Liabilities
729.14
751.81
720.20
675.56
490.10
401.24
385.07
491.90
657.79
641.60
Net Block
279.38
266.98
269.65
165.90
145.65
156.12
165.35
278.59
391.72
380.46
Gross Block
495.35
456.49
429.47
297.78
261.70
256.88
250.51
340.13
485.40
459.10
Accumulated Depreciation
215.97
189.52
159.82
131.89
116.05
100.76
85.15
61.54
93.68
78.64
Non Current Assets
280.19
267.92
280.06
166.72
147.15
157.32
169.44
282.47
401.72
380.46
Capital Work in Progress
0.00
0.36
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Non Current Investment
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
10.00
0.00
Long Term Loans & Adv.
0.82
0.59
10.41
0.83
1.50
1.20
4.08
3.88
0.00
0.00
Other Non Current Assets
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
448.95
483.88
440.15
508.83
342.95
243.93
215.63
209.42
255.87
260.65
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
218.12
190.09
167.79
130.11
102.59
77.69
73.36
67.22
104.52
119.08
Sundry Debtors
176.91
247.58
217.29
183.45
169.61
131.31
112.77
98.86
94.72
101.68
Cash & Bank
39.88
25.16
35.30
185.27
46.95
15.88
22.39
30.92
35.50
22.34
Other Current Assets
14.05
0.09
0.00
0.00
23.80
19.04
7.11
12.42
21.12
17.55
Short Term Loans & Adv.
14.00
20.96
19.76
10.01
23.80
19.04
7.11
12.41
21.12
17.55
Net Current Assets
215.86
187.82
180.71
222.60
23.83
-53.36
-303.63
-310.37
196.32
178.53
Total Assets
729.14
751.80
720.21
675.55
490.10
401.25
385.07
491.89
657.80
641.59

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
58.92
14.06
30.80
154.51
64.84
38.56
-62.30
-65.04
16.92
20.02
PBT
49.80
14.90
106.85
109.40
71.91
45.88
-178.84
-223.24
-10.04
-8.36
Adjustment
43.98
26.58
39.63
24.26
19.57
27.85
124.15
112.61
31.12
22.33
Changes in Working Capital
-27.40
-6.04
-88.14
20.27
-26.01
-35.18
-7.60
45.60
-4.16
6.04
Cash after chg. in Working capital
66.38
35.44
58.34
153.94
65.47
38.56
-62.30
-65.04
16.92
20.02
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-7.46
-21.37
-27.54
-0.89
-0.27
0.00
0.00
0.00
0.00
0.00
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-38.78
-20.73
-123.01
-33.19
-4.49
-5.43
-3.25
24.68
-35.33
-118.05
Net Fixed Assets
-5.86
-11.49
-22.01
-32.23
-2.62
-4.85
90.35
146.70
-24.61
-83.12
Net Investments
-1.78
-2.85
-163.82
0.00
0.00
-44.11
44.11
10.00
-10.06
-64.86
Others
-31.14
-6.39
62.82
-0.96
-1.87
43.53
-137.71
-132.02
-0.66
29.93
Cash from Financing Activity
-5.43
-3.47
-57.75
16.99
-29.28
-39.64
57.02
35.77
31.56
58.78
Net Cash Inflow / Outflow
14.71
-10.14
-149.96
138.32
31.07
-6.51
-8.53
-4.58
13.16
-39.24
Opening Cash & Equivalents
25.16
35.30
185.27
46.95
15.88
22.39
30.92
35.50
22.34
61.59
Closing Cash & Equivalent
39.88
25.16
35.30
185.27
46.95
15.88
22.39
30.92
35.50
22.34

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
11.50
10.59
10.79
8.97
3.34
1.89
-4.97
-2.14
4.01
3.71
ROA
4.83%
1.54%
11.86%
19.21%
16.52%
12.42%
-40.16%
-38.59%
-1.48%
-1.32%
ROE
7.92%
2.59%
20.45%
45.15%
73.02%
0.00%
0.00%
-645.23%
-6.78%
-6.04%
ROCE
10.60%
3.99%
23.16%
44.64%
38.30%
44.72%
-180.20%
-48.46%
1.77%
2.80%
Fixed Asset Turnover
1.92
1.73
2.46
2.85
2.43
1.73
1.20
0.74
0.76
0.91
Receivable days
84.88
110.59
81.87
80.88
87.17
101.60
108.63
115.71
99.74
84.47
Inventory Days
81.63
85.14
60.86
53.30
52.22
62.88
72.16
102.66
113.55
131.00
Payable days
51.56
65.56
54.58
56.06
48.85
59.34
68.51
70.79
80.56
80.72
Cash Conversion Cycle
114.94
130.17
88.15
78.13
90.54
105.14
112.28
147.58
132.73
134.75
Total Debt/Equity
0.25
0.25
0.19
0.23
1.12
1.88
-1.06
-2.87
2.64
2.65
Interest Cover
5.87
3.20
11.52
10.72
5.52
3.98
-2.27
-3.93
0.52
0.67

News Update:


  • USFDA conducts inspection at Marksans Pharma’s Goa facility
    7th Mar 2019, 14:09 PM

    The inspection of the facility took place between February 25 to March 6, 2019, resulting in a Form 483 with eight observations

    Read More
  • Marksans Pharma reports 44% rise in Q3 consolidated net profit
    8th Feb 2019, 12:48 PM

    Total income of the company increased by 13.57% at Rs 248.52 crore for Q3FY19

    Read More
  • Marksans Pharma - Quarterly Results
    8th Feb 2019, 12:31 PM

    Read More
  • UK MHRA grants Marketing Authorisation to Marksans Pharma’s arm
    5th Feb 2019, 14:48 PM

    UK MHRA has granted Marketing Authorisation to Relonchem, UK for Loratadine 5mg/5ml Oral Solution for the UK markets

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.